PLX PHARMA INC.
PLX PHARMA INC. (DPRX): 3 pipeline candidates · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.4 months
D/E 0.69 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for PLX PHARMA INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$25.8M
Quarterly Burn
$11.0M
Runway
7.4 mo
Revenue
$386K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in PLX PHARMA INC.'s pipeline?
PLX PHARMA INC. (DPRX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PLX PHARMA INC.'s lead drug candidate?
PLX PHARMA INC.'s most advanced tracked candidate is pl1100 (Phase 1) for pain and inflammation.
What is PLX PHARMA INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PLX PHARMA INC. has approximately 7.4 months of cash runway.
Who is the CEO of PLX PHARMA INC.?
Natasha Giordano is the chief executive officer of PLX PHARMA INC. (DPRX).
Get the full picture on PLX PHARMA INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.